Safety and efficiency of COVID-19 vaccine in North Africa

References

• Guo YR, Cao QD, Hong ZS, Tan YY, Chen SD, Jin HJ, Tan K-S, Wang D-Y, Yan Y. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak – an update on the status. Mil Med Res. 2020 Mars 13;7(1):11. doi:10.1186/s40779-020-00240-0.
   PubMed Web of Science ®Google Scholar
• Lai CC, Shih TP, Ko WC, Tang HJ, Hsueh PR. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): the epidemic and the challenges. Int J Antimicrob Agents. 2020 Mars 1;55(3):105924. doi:10.1016/j.ijantimicag.2020.105924.
   PubMed Web of Science ®Google Scholar
• Saeed BQ, Al-Shahrabi R, Alhaj SS, Alkokhardi ZM, Adrees AO. Side effects and perceptions following sinopharm COVID-19 vaccination. Int J Infect Dis. 2021 Oct 1;111:219–9. doi:10.1016/j.ijid.2021.08.013.
   PubMed Web of Science ®Google Scholar
• Ayouni I, Maatoug J, Dhouib W, Zammit N, Fredj SB, Ghammam R, Ghannem H. Effective public health measures to mitigate the spread of COVID-19: a systematic review. BMC Public Health. 2021 Mai 29;21(1):1015. doi:10.1186/s12889-021-11111-1.
   PubMed Web of Science ®Google Scholar
• novel-coronavirus-guidelines-non-pharmaceutical-measures_0.pdf [Internet] [cité 18 Sept 2023]. Disponible sur: https://www.ecdc.europa.eu/sites/default/files/documents/novel-coronavirus-guidelines-non-pharmaceutical-measures_0.pdf.
   Google Scholar
• Graham BS. Rapid COVID-19 vaccine development. Science 2020 Mai 29;368(6494):945–6. doi:10.1126/science.abb8923.
   PubMed Web of Science ®Google Scholar
• Ndwandwe D, Wiysonge CS. COVID-19 vaccines. Curr Opin Immunol. 2021 Août 1;71:111–16. doi:10.1016/j.coi.2021.07.003.
   PubMed Web of Science ®Google Scholar
• Han X, Xu P, Ye Q. Analysis of COVID-19 vaccines: types, thoughts, and application. J Clin Lab Anal. 2021;35(9):e23937. doi:10.1002/jcla.23937.
   PubMed Web of Science ®Google Scholar
• Forni G, Mantovani A. COVID-19 vaccines: where we stand and challenges ahead. Cell Death Differ. 2021 févr;28(2):626–39. doi:10.1038/s41418-020-00720-9.
   PubMed Web of Science ®Google Scholar
• Use authorization (EUA) for emergency use of moderna COVID‑19 vaccine for the prevention of COVID-19.pdf.
   Google Scholar
• Use authorization (EUA) for emergency use of pfizer-bioNTech COVID‑19 vaccine.pdf.
   Google Scholar
• CDC. Centers for Disease Control and Prevention. 2020 [cité 18 sept 2023]. COVID Data Tracker. Disponible sur: https://covid.cdc.gov/covid-data-tracker.
   Google Scholar
• Medeiros KS, Costa APF, Sarmento ACA, Freitas CL, Gonçalves AK. Side effects of COVID-19 vaccines: a systematic review and meta-analysis protocol of randomised trials. BMJ Open. 2022 févr 1;12(2):e050278. doi:10.1136/bmjopen-2021-050278.
   PubMed Web of Science ®Google Scholar
• Beatty AL, Peyser ND, Butcher XE, Cocohoba JM, Lin F, Olgin JE, Pletcher MJ, Marcus GM. Analysis of COVID-19 vaccine type and adverse effects following vaccination. JAMA Netw Open. 2021 déc 22;4(12):e2140364. doi:10.1001/jamanetworkopen.2021.40364.
   PubMed Web of Science ®Google Scholar
• Kimmel SR. Vaccine adverse events: separating myth from reality. Am Fam Physician. 2002 Déc 1;66(11):2113–20.
   Web of Science ®Google Scholar
• COVID-19 reinfection: are we ready for winter? eBioMedicine. [Internet]. 1 déc 2020; 62. [cité 22 sept 2023] Disponible sur. https://www.thelancet.com/journals/ebiom/article/PIIS2352-3964(20)30549-1/fulltext.
   Google Scholar
• Tunisia. WHO coronavirus disease (COVID-19) dashboard with vaccination data [Internet]. [cité 21 sept 2023]. Disponible sur. https://covid19.who.int.
   Google Scholar
• Accueil - Ministère de la santé publique. [Internet]. [cité 21 sept 2023]. Disponible sur. http://www.health.gov.tn/fr/.
   Google Scholar
• Hatmal MM, Al-Hatamleh MAI, Olaimat AN, Hatmal M, Alhaj-Qasem DM, Olaimat TM, Mohamud R. Side effects and perceptions following COVID-19 vaccination in Jordan: a randomized, cross-sectional study implementing machine learning for predicting severity of side effects. Vaccines (Basel). 2021 Mai 26;9(6):556. doi:10.3390/vaccines9060556.
   PubMed Web of Science ®Google Scholar
• Salehi-Vaziri M, Pouriayevali MH, Fotouhi F, Jalali T, Banifazl M, Farahmand B, Larijani MS, Ahmadi Z, Fereydouni Z, Tavakoli M, et al. SARS-CoV-2 re-infection rate in Iranian COVID-19 cases within one-year follow-up. Microb Pathog. 2021 déc;161(Pt B):105296. doi:10.1016/j.micpath.2021.105296.
   Google Scholar
• Nazli A, Emecen AN, Kutlusoylu OOE, Simsek GO, Alpaydin AO, Bayram B, Appak Ö, Ünal B, Yapar N, Avkan Oğuz V. et al. Hafif Seyirli COVID-19 Hastalarının İnfeksiyondan Altı Ay Sonraki Mortalite ve Reinfeksiyon Oranları. Flora Infeksiyon Hastaliklari Ve Klinik Mikrobiyoloji Dergisi. 2021;26(2):267–76. doi:10.5578/flora.20219806.
   Google Scholar
• Arslan F, Isık Goren B, Baysal B, Vahaboğlu H. Is vaccination necessary for COVID-19 patients? A retrospective cohort study investigating reinfection rates and symptomatology in a tertiary hospital. Expert Rev Vacc. 2022 Févr;21(2):249–52. doi:10.1080/14760584.2022.2012457.
   PubMed Web of Science ®Google Scholar
• Pilz S, Chakeri A, Ioannidis JP, Richter L, Theiler-Schwetz V, Trummer C, Krause R, Allerberger F. SARS-CoV-2 re-infection risk in Austria. Eur J Clin Invest. 2021 avr;51(4):e13520. doi:10.1111/eci.13520.
   PubMed Web of Science ®Google Scholar
• Piri SM, Edalatfar M, Shool S, Jalalian MN, Tavakolpour S. A systematic review on the recurrence of SARS-CoV-2 virus: frequency, risk factors, and possible explanations. Infect Dis (Lond). 2021 Mai;53(5):315–24. doi:10.1080/23744235.2020.1871066.
   PubMed Web of Science ®Google Scholar
• The different types of COVID-19 vaccines. [Internet]. [cité 13 sept 2023]. Disponible sur. https://www.who.int/news-room/feature-stories/detail/the-race-for-a-covid-19-vaccine-explained.
   Google Scholar
• Calina D, Docea AO, Petrakis D, Egorov AM, Ishmukhametov AA, Gabibov AG, Shtilman M, Kostoff R, Carvalho F, Vinceti M, et al. Towards effective COVID‑19 vaccines: Updates, perspectives and challenges (Review). Int J Mol Med. 2020 Juill 1;46(1):3–16. doi:10.3892/ijmm.2020.4596.
   PubMed Web of Science ®Google Scholar
• ONMNE Tunisie | Ministère de la santé. [Internet]. [cité 6 janv 2024]. Disponible sur. https://www.onmne.tn/.
   Google Scholar
• StatCounter Global Stats. [Internet]. [cité 25 sept 2023]. Social Media Stats Tunisia. Disponible sur. https://gs.statcounter.com/social-media-stats/all/tunisia.
   Google Scholar
• Santé des femmes. [Internet]. [cité 25 sept 2023]. Disponible sur. https://www.who.int/fr/news-room/fact-sheets/detail/women-s-health.
   Google Scholar
• Brouqui P, Colson P, Melenotte C, Houhamdi L, Bedotto M, Devaux C, Gautret P, Million M, Parola P, Stoupan D, et al. COVID‐19 re‐infection. Eur J Clin Invest. 2021 Mai;51(5):e13537. doi:10.1111/eci.13537.
   Web of Science ®Google Scholar
• Abu-Raddad LJ, Chemaitelly H, Bertollini R. Severity of SARS-CoV-2 reinfections as compared with primary infections. N Engl J Med. 2021 Nov 24;385(26):2487–9. doi:10.1056/NEJMc2108120.
   Web of Science ®Google Scholar
• A clinical case definition of post COVID-19 condition by a delphi consensus. 2021 Oct 6. [Internet]. [cité 13 sept 2023]. Disponible sur. https://www.who.int/publications-detail-redirect/WHO-2019-nCoV-Post_COVID-19_condition-Clinical_case_definition-2021.1.
   Google Scholar
• Offit PA, Davis RL, Gust D. Vaccine safety. Vaccines. 2008; 74:1629–50.
   Google Scholar
• Almufty HB, Mohammed SA, Abdullah AM, Merza MA. Potential adverse effects of COVID-19 vaccines among Iraqi population; a comparison between the three available vaccines in Iraq; a retrospective cross-sectional study. Diabetes Metab Syndr. 2021;15(5):102207. doi:10.1016/j.dsx.2021.102207.
   Web of Science ®Google Scholar
• Attash HM, Al-Obaidy LM, Al-Qazaz H. Which type of the promising COVID-19 vaccines produces minimal adverse effects? A retrospective cross-sectional study. Vaccines (Basel). 2022 Janv 25 ;10(2):186. doi:10.3390/vaccines10020186.
   Web of Science ®Google Scholar
• Omeish H, Najadat A, Al-Azzam S, Tarabin N, Abu Hameed A, Al-Gallab N, Abbas H, Rababah L, Rabadi M, Karasneh R, et al. Reported COVID-19 vaccines side effects among Jordanian population: a cross sectional study. Hum Vaccin Immunother. 2022 Déc 31;18(1):1981086. doi:10.1080/21645515.2021.1981086.
   PubMed Web of Science ®Google Scholar
• Zahid MN. Unfolding the mild to moderate short-term side effects of four COVID-19 vaccines used in Bahrain: a cross-sectional study. Vaccines (Basel). 2021 Nov 22;9(11):1369. doi:10.3390/vaccines9111369.
   Web of Science ®Google Scholar
• Al Khames Aga QA, Alkhaffaf WH, Hatem TH, Nassir KF, Batineh Y, Dahham AT, Shaban D, Al Khames Aga LA, Agha MYR, Traqchi M, et al. Safety of COVID‐19 vaccines. J Med Virol. 2021 déc;93(12):6588–94. doi:10.1002/jmv.27214.
   Web of Science ®Google Scholar
• Jayadevan R, Shenoy R, Ts A. Survey of symptoms following COVID-19 vaccination in India. [Internet]. medRxiv. 2021. [cité 4 janv 2024]. p. 2021.02.08.21251366. Disponible sur:. https://www.medrxiv.org/content/10.1101/2021.02.08.21251366v1.
   Google Scholar
• Oudjedi A, Allali A, Bekli A, Lounis M, Ben Saad H, Boukoufa M. Reported COVID-19 vaccines side effects among Algerian athletes: a comparison between inactivated virus, adenoviral vector, and mRNA COVID-19 vaccines. Phys Sportsmed. 2023 mars 6;1–13. doi:10.1080/00913847.2023.2186691.
   Web of Science ®Google Scholar
• Hervé C, Laupèze B, Del Giudice G, Didierlaurent AM, Tavares Da Silva F. The how’s and what’s of vaccine reactogenicity. NPJ Vaccines. 2019 Sept 29;4(1):39. doi:10.1038/s41541-019-0132-6.
   PubMed Web of Science ®Google Scholar
• Menni C, Klaser K, May A, Polidori L, Capdevila J, Louca P, Sudre CH, Nguyen LH, Drew DA, Merino J, et al. Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID symptom study app in the UK: a prospective observational study. Lancet Infect Dis. 2021 Juill 1;21(7):939–49. doi:10.1016/S1473-3099(21)00224-3.
   PubMed Web of Science ®Google Scholar
• Ganesan S, Al Ketbi LMB, Al Kaabi N, Al Mansoori M, Al Maskari NN, Al Shamsi MS, Alderei AS, El Eissaee HN, Al Ketbi RM, Al Shamsi NS. et al. Vaccine side effects following COVID-19 vaccination among the residents of the UAE—an observational study. Front Public Health. [Internet]. 2022;10 [cité 21 sept 2023]. Disponible sur. . https://www.frontiersin.org/articles/10.3389/fpubh.2022.876336.
   Web of Science ®Google Scholar
• Baden LR, El Sahly HM, Essink B, Kotloff K, Frey S, Novak R, Diemert D, Spector SA, Rouphael N, Creech CB, et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N Engl J Med. 2021 févr 4;384(5):403–16. doi:10.1056/NEJMoa2035389.
   PubMed Web of Science ®Google Scholar
• Iguacel I, Maldonado AL, Ruiz-Cabello AL, Casaus M, Moreno LA, Martínez-Jarreta B. Association between COVID-19 vaccine side effects and body mass index in Spain. Vaccines. 2021 Nov;9(11):1321. doi:10.3390/vaccines9111321.
   Web of Science ®Google Scholar
• SeyedAlinaghi S, Karimi A, Pashaei Z, Afzalian A, Mirzapour P, Ghorbanzadeh K, Ghasemzadeh A, Dashti M, Nazarian N, Vahedi F, et al. Safety and adverse events related to COVID-19 mRNA vaccines; A systematic review. Arch Acad Emerg Med. 2022 Mai 22;10(1):e41.
   Google Scholar
• Pardi N, Hogan MJ, Porter FW, Weissman D. mRNA vaccines – a new era in vaccinology. Nat Rev Drug Discov avr. 2018;17(4):261–79. doi:10.1038/nrd.2017.243.
   PubMed Web of Science ®Google Scholar
• Lounis M, Rais MA, Bencherit D, Aouissi HA, Oudjedi A, Klugarová J, Pokorná A, Klugar M, Riad A. Side effects of COVID-19 inactivated virus vs. adenoviral vector vaccines: Experience of Algerian healthcare workers. Front Public Health. 2022;10:896343. doi:10.3389/fpubh.2022.896343.
   PubMed Web of Science ®Google Scholar
• Lounis M, Aouissi HA, Abdelhadi S, Rais MA, Belkessa S, Bencherit D. Short-term adverse effects following booster dose of inactivated-virus vs. adenoviral-vector COVID-19 vaccines in Algeria: a cross-sectional study of the general population. Vaccines (Basel). 2022 Oct 22;10(11):1781. doi:10.3390/vaccines10111781.
   Web of Science ®Google Scholar
• Chapin-Bardales J, Gee J, Myers T. Reactogenicity following receipt of mRNA-based COVID-19 vaccines. JAMA. 2021 Juin 1;325(21):2201–2. doi:10.1001/jama.2021.5374.
   PubMed Web of Science ®Google Scholar
• Rojas-Pérez-Ezquerra P, Crespo Quirós J, Tornero Molina P, Baeza Ochoa de Ocáriz ML, Zubeldia Ortuño JM. Safety of new mRNA vaccines against COVID-19 in severely allergic patients. J Investig Allergol Clin Immunol. 2021 Avr 20;31(2):180–1. doi:10.18176/jiaci.0683.
   Web of Science ®Google Scholar
• Mahallawi WH, Mumena WA. Reactogenicity and immunogenicity of the pfizer and astraZeneca COVID-19 vaccines. Front Immunol. 2021;12:794642. doi:10.3389/fimmu.2021.794642.
   PubMed Web of Science ®Google Scholar
• Bae S, Lee YW, Lim SY, Lee JH, Lim JS, Lee S, Park S, Kim S-K, Lim Y-J, Kim EO. et al. Adverse reactions following the first dose of ChAdOx1 nCoV-19 vaccine and BNT162b2 vaccine for healthcare workers in South Korea. J Korean Med Sci. [Internet] 2021 Avr 16;36:17 [cité 19 Sept 2023]. Disponible sur. 36.17: https://synapse.koreamed.org/articles/1146962.
   Web of Science ®Google Scholar
• Lee YW, Lim SY, Lee JH, Lim JS, Kim M, Kwon S, Joo J, Kwak SH, Kim EO, Jung J. et al. Adverse reactions of the second dose of the BNT162b2 mRNA COVID-19 vaccine in healthcare workers in Korea. J Korean Med Sci. 2021 Mai 14;36:21 [cité 19 Sept 2023] [Internet]. Disponible sur. https://synapse.koreamed.org/articles/1147011.
   Web of Science ®Google Scholar
• Riad A, Hocková B, Kantorová L, Slávik R, Spurná L, Stebel A, Havriľak M, Klugar M. Side effects of mRNA-based COVID-19 vaccine: Nationwide phase IV study among healthcare workers in Slovakia. Pharm (Basel). 2021 Août 29;14(9):873. doi:10.3390/ph14090873.
   Google Scholar
• Di Resta C, Ferrari D, Viganò M, Moro M, Sabetta E, Minerva M, Ambrosio A, Locatelli M, Tomaiuolo R. The gender impact assessment among healthcare workers in the SARS-CoV-2 vaccination—an analysis of serological response and side effects. Vaccines. 2021 Mai;9(5):522. doi:10.3390/vaccines9050522.
   Web of Science ®Google Scholar
• Colgrove J. Immunity for the people: the challenge of achieving high vaccine coverage in American history. Public Health Rep. 2007;122(2):248–57. doi:10.1177/003335490712200215.
   PubMed Web of Science ®Google Scholar
• Yahav D, Yelin D, Eckerle I, Eberhardt CS, Wang J, Cao B, Kaiser L. Definitions for coronavirus disease 2019 reinfection, relapse and PCR re-positivity. Clin Microbiol Infect. 2021 Mars;27(3):315–8. doi:10.1016/j.cmi.2020.11.028.
   PubMed Web of Science ®Google Scholar
• Pulliam JRC, van Schalkwyk C, Govender N, von Gottberg A, Cohen C, Groome MJ, Dushoff J, Mlisana K, Moultrie H. Increased risk of SARS-CoV-2 reinfection associated with emergence of omicron in South Africa [Internet]. medRxiv. 2022. [cité 23 sept 2023]. p. 2021.11.11.21266068. Disponible sur. https://www.medrxiv.org/content/10.1101/2021.11.11.21266068v3.
   Google Scholar
• Sotoodeh Ghorbani S, Taherpour N, Bayat S, Ghajari H, Mohseni P, Hashemi Nazari SS. Epidemiologic characteristics of cases with reinfection, recurrence, and hospital readmission due to COVID-19: A systematic review and meta-analysis. J Med Virol. 2022 janv;94(1):44–53. doi:10.1002/jmv.27281.
   PubMed Web of Science ®Google Scholar
• Slezak J, Bruxvoort K, Fischer H, Broder B, Ackerson B, Tartof S. Rate and severity of suspected SARS-Cov-2 reinfection in a cohort of PCR-positive COVID-19 patients. Clin Microbiol Infect. 2021 Déc 1;27(12):1860.7–10. doi:10.1016/j.cmi.2021.07.030.
   Web of Science ®Google Scholar
• Jain VK, Iyengar K, Garg R, Vaishya R. Elucidating reasons of COVID-19 re-infection and its management strategies. Diabetes Metab Syndr. 2021 Mai 1;15(3):1001–6. doi:10.1016/j.dsx.2021.05.008.
   Web of Science ®Google Scholar
• Cavanaugh AM, Spicer KB, Thoroughman D, Glick C, Winter K. Reduced risk of reinfection with SARS-CoV-2 After COVID-19 vaccination — Kentucky, May–June 2021. MMWR Morb Mortal Wkly Rep. 2021 Août 13;70(32):1081–3. doi:10.15585/mmwr.mm7032e1.
   PubMed Web of Science ®Google Scholar
• Shrestha NK, Burke PC, Nowacki AS, Terpeluk P, Gordon SM. Necessity of coronavirus disease 2019 (COVID-19) vaccination in persons who have already had COVID-19. Clin Infect Dis. 2022 Août 24;75(1):e662‑71.
   Web of Science ®Google Scholar
• Rahman S, Rahman MM, Miah M, Begum MN, Sarmin M, Mahfuz M, Hossain ME, Rahman MZ, Chisti MJ, Ahmed T. et al. COVID-19 reinfections among naturally infected and vaccinated individuals. Sci Rep. 2022 Janv 26;12(1):1438. doi: 10.1038/s41598-022-05325-5.
   Web of Science ®Google Scholar
• Saadat S, Rikhtegaran Tehrani Z, Logue J, Newman M, Frieman MB, Harris AD, Sajadi MM. Binding and neutralization antibody titers after a single vaccine dose in health care workers previously infected with SARS-CoV-2. JAMA. 2021 Avr 13;325(14):1467–9. doi:10.1001/jama.2021.3341.
   PubMed Web of Science ®Google Scholar
• Altawalah H. Antibody responses to natural SARS-CoV-2 infection or after COVID-19 vaccination. Vaccines août. 2021;9(8):910. doi:10.3390/vaccines9080910.
   Web of Science ®Google Scholar
• Arslan Y, Akgul F, Sevim B, Varol ZS, Tekin S. Re-infection in COVID-19: do we exaggerate our worries?. Eur J Clin Invest. 2022;52(6):e13767. doi:10.1111/eci.13767.
   Web of Science ®Google Scholar
• Knoll MD, Wonodi C. Oxford–AstraZeneca COVID-19 vaccine efficacy. Lancet. 2021 Janv 9;397(10269):72–4. doi:10.1016/S0140-6736(20)32623-4.
   PubMed Web of Science ®Google Scholar
• Kim JH, Marks F, Clemens JD. Looking beyond COVID-19 vaccine phase 3 trials. Nat Med. 2021 Févr;27(2):205–11. doi:10.1038/s41591-021-01230-y.
   PubMed Web of Science ®Google Scholar
• Rotshild V, Hirsh-Raccah B, Miskin I, Muszkat M, Matok I. Comparing the clinical efficacy of COVID-19 vaccines: a systematic review and network meta-analysis. Sci Rep. 2021 Nov 23 ;11(1):22777. doi:10.1038/s41598-021-02321-z.
   PubMed Web of Science ®Google Scholar
• Premikha M, Chiew CJ, Wei WE, Leo YS, Ong B, Lye DC, Lee VJ, Tan KB. Comparative effectiveness of mRNA and inactivated whole-virus vaccines against coronavirus disease 2019 infection and severe disease in Singapore. Clin Infect Dis. 2022 Avr 12;75(8):1442–5. ciac288. doi:10.1093/cid/ciac288.
   PubMed Web of Science ®Google Scholar
• Ul Munamm SA, Nadeem I, Mahdi N, Saqlain M, Rana ZK, Khatana UF, Bhatty UM, Navayogaarajah V, Khan FM, Ur Rasool M. et al. Comparative analysis of mRNA and inactivated COVID-19 vaccines: a study from Faisalabad district of Pakistan. J R Coll Physicians Edinb. 2022 Sept;52(3):240–6. doi:10.1177/14782715221131409.
   Web of Science ®Google Scholar
• Piernas C, Patone M, Astbury NM, Gao M, Sheikh A, Khunti K, Shankar-Hari M, Dixon S, Coupland C, Aveyard P. et al. Associations of BMI with COVID-19 vaccine uptake, vaccine effectiveness, and risk of severe COVID-19 outcomes after vaccination in England: a population-based cohort study. Lancet Diabetes Endocrinol. 2022 Août 1;10(8):571–80. doi:10.1016/S2213-8587(22)00158-9.
   PubMed Web of Science ®Google Scholar
• Townsend MJ, Kyle TK, Stanford FC. COVID-19 Vaccination and obesity: Optimism and challenges. Obesity (Silver Spring). 2021 Avr;29(4):634–5. doi:10.1002/oby.23131.
   Web of Science ®Google Scholar
• Wilder-Smith A, Frahsa A. Impact of BMI on COVID-19 vaccine effectiveness. Lancet Diabetes Endocrinol. 2022 Août 1;10(8):551–2. doi:10.1016/S2213-8587(22)00170-X.
   Google Scholar
• Nasr MJC, Geerling E, Pinto AK. Impact of obesity on vaccination to SARS-CoV-2. Front Endocrinol (Lausanne). 2022;13:898810. doi:10.3389/fendo.2022.898810.
   Web of Science ®Google Scholar
• Pellini R, Venuti A, Pimpinelli F, Abril E, Blandino G, Campo F, Conti L, De Virgilio A, De Marco F, Di Domenico EG, et al. Initial observations on age, gender, BMI and hypertension in antibody responses to SARS-CoV-2 BNT162b2 vaccine. EClinicalMedicine juin. 2021;36:100928. doi:10.1016/j.eclinm.2021.100928.
   PubMedGoogle Scholar
• Watanabe M, Balena A, Masi D, Tozzi R, Risi R, Caputi A, Rossetti R, Spoltore ME, Biagi F, Anastasi E, et al. Rapid weight loss, central obesity improvement and blood glucose reduction are associated with a stronger adaptive immune response following COVID-19 mRNA vaccine. Vaccines (Basel). 2022 Janv 5;10(1):79. doi: 10.3390/vaccines10010079.
   Web of Science ®Google Scholar
• Fu C, Lin N, Zhu J, Ye Q. Association between overweight/obesity and the safety and efficacy of COVID-19 vaccination: A systematic review. Vaccines (Basel). 2023 Mai 17;11(5):996. doi:10.3390/vaccines11050996.
   Web of Science ®Google Scholar
• Fakhroo A, AlKhatib HA, Al Thani AA, Yassine HM. Reinfections in COVID-19 patients: impact of virus genetic variability and host immunity. Vaccines. 2021 Oct;9(10):1168. doi:10.3390/vaccines9101168.
   Web of Science ®Google Scholar
• Bowe B, Xie Y, Al-Aly Z. Acute and postacute sequelae associated with SARS-CoV-2 reinfection. Nat Med. 2022 Nov;28(11):2398–405. doi:10.1038/s41591-022-02051-3.
   PubMed Web of Science ®Google Scholar
• Davis HE, McCorkell L, Vogel JM, Topol EJ. Long COVID: major findings, mechanisms and recommendations. Nat Rev Microbiol. 2023 Mars;21(3):133–46. doi:10.1038/s41579-022-00846-2.
   PubMed Web of Science ®Google Scholar
• Deng L, Li P, Zhang X, Jiang Q, Turner D, Zhou C, Gao Y, Qian F, Zhang C, Lu H, et al. Risk of SARS-CoV-2 reinfection: a systematic review and meta-analysis. Sci Rep. 2022 Déc 1;12(1):20763. doi:10.1038/s41598-022-24220-7.
   Google Scholar
• Cohen C, Pulliam J. COVID-19 infection, reinfection, and the transition to endemicity. Lancet. 2023 Mars 11;401(10379):798–800. doi:10.1016/S0140-6736(22)02634-4.
   Web of Science ®Google Scholar
• Mahase E. Long covid could be four different syndromes, review suggests. BMJ. 2020 Oct 14;371:m3981. doi:10.1136/bmj.m3981.
   Google Scholar